In Dutch and Danish patients with FIGO III ovarian carcinoma, geographic survival differences are associated with differences in quantitative pathologic features

International Journal of Gynecological Cancer

Volumn 6, Issue 2, 1996, Pages 108-114

  Brinkhuis, M ^a   Baak, J P A ^a   Van Diest, P J ^a   Lund, B ^b   Wils, J ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Mental Health Services CPH   (Denmark)

^c LAURENTIUS HOSPITAL   (Netherlands)

Author keywords

geographic survival differences; morphometry; ovarian cancer; prognosis; stereology

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DENMARK; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; NETHERLANDS; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; STEREOLOGY; SURVIVAL TIME;

EID: 0029877918     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1996.06020108.x     Document Type: Article

References (26)

1. La Vecchia C, Levi F, Lucchini F, Negri E, Franceschi S. Descriptive epidemiology of ovarian cancer in Europe. Gynecol Oncol 1992; 46: 208-15.
2. Parazzini F, Franceschi S, La Vecchia C, Fasoli M. The epidemiology of ovarian cancer. Gynecol Oncol 1991; 43: 9-23.
3. Visser O, Coebergh JWW, Schouten LJ, (ed). Incidence of Cancer in the Netherlands 1990. Second Report of the Netherlands Cancer Registry Utrecht: Netherlands Cancer Registry, 1993.
4. KyÆr SK, Storm HH. Female genital organs. APMIS 1993; 33: 107-21.
5. Baker TR, Piver MS, Hempling RE. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer 1994; 74: 656-63.
6. Friedlander ML, Dembo AJ. Prognostic factors in ovarian cancer. Semm Oncol 1991; 18: 205-12.
7. Voest EE, Houwelingen JC van, Neijt JP. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk) as main objectives. Eur J Clin Oncol 1989; 25: 711-20.
8. Einhorn N, Nilsson B, Sjövall K. Factors influencing survival in carcinoma of the ovary: Study from a well defined swedish population. Cancer 1985; 55: 2019-25
9. Lund B, Williamson P. Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann Oncol 1991; 2: 281-7.
10. Stalsberg H, Abeler V, Blom GP, Bostad L, Skarland E, Westgaard G. Observer variation in histologic classification of malignant and borderline ovarian tumors. Hum Pathol 1988; 19: 1030-5.
11. Lund B, Williamson P, Houwelingen HC van, Neijt JP. Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma. Cancer Res 1990; 50: 4626-9.
12. Baak JPA, Langley FA, Talerman A, Delemarre JFM. The prognostic variability of ovarian tumor grading by different pathologists. Gynecol Oncol 1987; 27: 166-72.
13. Baak JPA, Schipper NW, Wisse-Brekelmans, et al. The prognostic value of morphometrical features and cellular DNA content in cis-platin treated late ovarian cancer patients. Br J Cancer 1988; 57: 503-8.
14. Diest PJ van, Baak JPA, Brugghe J, et al. Quantitative prognostic features as predictors of long-term survival in patients with advanced ovarian cancer treated with cisplatin. Int J Gynecol Cancer 1994; 3: 174-80.
15. Rodenburg CJ, Cornelisse CJ, Hermans J, Fleuren GJ. DNA flow cytometry and morphometry as prognostic indicators in advanced ovarian cancer: A step forward in predicting the clinical outcome. Gynecol Oncol 1988; 29: 176-87.
16. Haapasalo H, Collan Y, Seppä A, Gidlund A-L, Atkin NB, Pesonen E. Prognostic value of ovarian grading methods - a method comparison study. Histopathology 1990; 16: 1-7.
17. Haapasalo H, Atkin NB, Collan Y, Pesonen E, Paljärvi L. Tumor ploidy, morphometry, histological and clinical features in ovarian carcinoma: mutual relations. Anal Cell Pathol 1991 3: 261-71.
18. Högbert T, Wang G, Risberg B, et al. Nuclear morphometry: A strong prognostic factor for survival after secondary surgery in advanced ovarian cancer. Int J Gynecol Cancer 1992; 2: 198-206.
19. Ludescher C, Weger A-R, Lindholm J, et al. Prognostic significance of tumor cell morphometry, histopathology and clinical parameters in advanced carcinoma. Int J Gynecol Pathol 1990; 9: 343-51.
20. Weger AR, Ludescher C, Mikuz G, et al. The value of prognostic indicators in advanced ovarian cancer. Pathol Res Pract 1989; 185: 676-9.
21. Mogensen O, Sørensen FB, Bichel P, Jakobsen A. Nuclear volume and prognosis in ovarian cancer. Int J Gynecol Cancer 1992; 2: 141-6.
22. Brinkhuis M, Mogensen O, Bichel P, Baak JPA. The significance of differences in prognostic value of quantitative pathologic features in FIGO III and IV serous adenocarcinoma of the ovary between a group of Danish patients and other groups. Int J Gynecol Cancer 1995; 5: 355-60.
23. Baak JPA, Wisse-Brekelmans ECM, Kurver PHJ, Gorp van LHM, Voorhorst FJ, Miettinen OS. Regional differences in breast cancer survival are correlated with differences in differentiation and rate of proliferation. Hum Pathol 1992; 23: 989-92.
24. Baak JPA, Chan KK, Stolk JG, Kenemans P. Prognostic factors in borderline and invasive ovarian tumours of the common epithelial type. Path Res Pract 1987; 182: 755-74.
25. Serov SF, Scully RE, Sobin LH. Histological Typing of Ovarian Tumors. Geneva: World Heath Organization, 1973: 17-18.
26. Rosen PP, Ashikari R, Thaler, et al. A comparative study of some pathologic features of mammary carcinoma in Tokyo, Japan and New York, USA. Cancer 1977; 39: 429-34.